
Disease & Drugs
Clinical Trials
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Clinical Trials
Clinical TrialsAgenus Reports 36% Major Response With BOT+BAL in Colon CancerAgenus’ Phase 2 UNICORN trial demonstrated a 36% major pathological response rate and 29% pathological complete response rate with neoadjuvant botensilimab plus balstilimab in pMMR/MSS colon cancer.Fact-Checked
Clinical TrialsTeva to Stop TOPAS-MSA Trial After Interim Futility FindingTeva Pharmaceuticals will discontinue its Phase 2 TOPAS-MSA trial evaluating emrusolmin in multiple system atrophy after an independent monitoring committee recommended stopping the study following a prespecified interim…Fact-Checked
Clinical TrialsMilestone Reports 66.7% PSVT Conversion With CARDAMYST After AblationMilestone Pharmaceuticals reported Phase 3 RAPID subgroup findings showing that CARDAMYST (etripamil) nasal spray converted recurrent paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm within 30 minutes in four…Fact-Checked
Clinical TrialsEnlivex Reports 79.2% Allocetra Response in Older Knee OA PatientsEnlivex reported 12-month Phase IIa results for Allocetra in knee osteoarthritis, with 79.2% of patients aged 64 and older achieving a clinically meaningful response compared with 47.6% receiving…Fact-Checked
Clinical TrialsLilly’s AtaiBeckley Reports Positive Mebufotenin Results in Depression TrialAtaiBeckley’s investigational intranasal mebufotenin, based on 5-MeO-DMT, a naturally occurring psychedelic found in Sonoran Desert toad secretions, demonstrated significant antidepressant effects in a 193-participant Phase 2b trial.Fact-Checked
Clinical TrialsInventisBio’s D-2570 Delivers Up to 90% PASI 75 Response in Psoriasis TrialInventisBio’s oral TYK2 inhibitor D-2570 demonstrated significant improvements in PASI 75, PASI 90 and PASI 100 responses in a Phase 2 trial involving patients with moderate-to-severe plaque psoriasis.…Fact-Checked
Clinical TrialsAtom’s Lingdolinurad Delivers Strong Phase 2b Gout ResultsAtom Therapeutics’ lingdolinurad achieved higher serum urate target attainment than febuxostat in a Phase 2b gout study, with 91.9% of patients reaching the primary urate target at Week…Fact-Checked
Clinical TrialsAbbott Reports Strong TECTONIC Results for SonicForce IVLAbbott’s pivotal TECTONIC trial met both primary endpoints, reporting 97% procedural success and a 0.3% 30-day target lesion failure rate with its investigational SonicForce coronary intravascular lithotripsy system.…Fact-Checked
Clinical TrialsAer Therapeutics Reports Phase 2a Failure for Fexlamose in COPDAer Therapeutics’ investigational therapy fexlamose failed to meet its Phase 2a efficacy endpoints in moderate-to-severe COPD, showing no improvement in pulmonary function or overall mucus-plug burden after 28…Fact-Checked
Clinical TrialsRegeneron’s Libtayo Maintains DFS Benefit in Longer-Term C-POST ResultsLonger-term Phase 3 C-POST findings showed sustained disease-free survival benefit with adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma.Fact-Checked
Clinical TrialsSobi Reports Positive REDUCE-2 Results for PozdeutinuradSobi’s Phase 3 REDUCE-2 study found that pozdeutinurad 75 mg and 50 mg achieved significantly higher serum urate target rates than placebo at month 6, with reductions sustained…Fact-Checked
Clinical TrialsAcumen Reports Sabirnetug Failure Despite Amyloid ReductionAcumen Pharmaceuticals reported that sabirnetug (ACU193) failed to demonstrate clinical benefit in the Phase 2 ALTITUDE-AD trial at either dose, despite significant amyloid plaque reduction.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.